Pharmaceutical company Aradigm Corporation (NASDAQ:ARDM) disclosed on Friday the addition of Theresa Matkovits PhD to the board's audit committee and the nominating and corporate governance committee.
Currently, Dr Matkovits serves as the chief operating officer of ContraVir Pharmaceuticals as well as as a member of the board director of BioSurplus.
Most recently, Dr Matkovits has worked as Chief Operating Officer as well as Executive Vice President, Head of Drug Development at ContraVir.
Previously, Dr Matkovits was employed as the Research and Development Programme Leader at NPS Pharmaceuticals (NPS), vice president, Innovation Leader for Infectious Disease at The Medicines Company, as well as executive director, head of Strategic Planning and Operations for Novartis.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy